What Differs between Patients under Methadone and under Buprenorphine for Opioid Use Disorder (OUD) in Daily Clinical Practice in France? A Short Report
Abstract
:1. Introduction
2. Materials and Methods
2.1. Procedure and Ethics
2.2. Participants
2.3. Measures
2.3.1. Sociodemographic Characteristics
2.3.2. OUD Characteristics
2.3.3. Use of other substances and gambling habits
2.3.4. Statistical Analysis
3. Results
3.1. Descriptive Analysis of the Sample
3.2. Comparative Analysis
3.3. Multivariate Analysis-Logistic Regression
4. Discussion
Strengths and Weaknesses
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Hasin, D.S.; O’Brien, C.P.; Auriacombe, M.; Borges, G.; Bucholz, K.; Budney, A.; Compton, W.M.; Crowley, T.; Ling, W.; Petry, N.M.; et al. DSM-5 criteria for substance use disorders: Recommendations and rationale. Am. J. Psychiatry 2013, 170, 834–851. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Paulozzi, L.J.; Zhang, K.; Jones, C.M.; Mack, K.A. Risk of adverse health outcomes with increasing duration and regularity of opioid therapy. J. Am. Board. Fam. Med. 2014, 27, 329–338. [Google Scholar] [CrossRef] [PubMed]
- Dematteis, M.; Auriacombe, M.; D’Agnone, O.; Somaini, L.; Szerman, N.; Littlewood, R.; Alam, F.; Alho, H.; Benyamina, A.; Bobes, J.; et al. Recommendations for buprenorphine and methadone therapy in opioid use disorder: A European consensus. Expert Opin. Pharmacother. 2017, 18, 1987–1999. [Google Scholar] [CrossRef] [PubMed]
- Landreat, M.G.; Rozaire, C.; Guillet, J.Y.; Vigneau, C.V.; Le Reste, J.Y.; Bronnec, M.G. French Experience with Buprenorphine: Do Physicians Follow the Guidelines? PLoS ONE 2015, 10, e0137708. [Google Scholar]
- Fatseas, M.; Auriacombe, M. Why buprenorphine is so successful in treating opiate addiction in France. Curr. Psychiatry Rep. 2007, 9, 358–364. [Google Scholar] [CrossRef] [PubMed]
- ANAES. Stratégies thérapeutiques pour les personnes dépendantes des opiacés: Place des traitements de substitution. Presse Méd. 2004, 33, 41–47. [Google Scholar] [CrossRef]
- British Columbia Centre on Substance Use and British Columbia Ministry of Health (C.O.P.A.S.O.B.). Methadone and Buprenorphine: Clinical Practice Guideline for Opioid Use Disorder; British Columbia Centre on Substance Use and British Columbia Ministry of Health: Vancouver, BC, Canada, 2017. [Google Scholar]
- Grall-Bronnec, M.; Laforgue, E.J.; Challet-Bouju, G.; Cholet, J.; Hardouin, J.B.; Leboucher, J.; Guillou-Landreat, M.; Victorri-Vigneau, C. Prevalence of Coaddictions and Rate of Successful Treatment Among a French Sample of Opioid-Dependent Patients with Long-Term Opioid Substitution Therapy: The OPAL Study. Front. Psychiatry 2019, 10, 726. [Google Scholar] [CrossRef] [PubMed]
- Victorri-Vigneau, C.; Verstuyft, C.; Bouquie, R.; Laforgue, E.J.; Hardouin, J.B.; Leboucher, J.; Le Geay, B.; Dano, C.; Challet-Bouju, G.; Grall-Bronnec, M. Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study. Br. J. Clin. Pharmacol. 2019, 85, 1538–1543. [Google Scholar] [CrossRef] [PubMed]
- Heatherton, T.F.; Kozlowski, L.T.; Frecker, R.C.; Fagerstrom, K.O. The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. Br. J. Addict. 1991, 86, 1119–1127. [Google Scholar] [CrossRef] [PubMed]
- Karila, L.; Legleye, S.; Beck, F.; Corruble, E.; Falissard, B.; Reynaud, M. Validation of a questionnaire to screen for harmful use of alcohol and cannabis in the general population: CRAFFT-ADOSPA. Presse Med. 2007, 36, 582–590. [Google Scholar] [CrossRef] [PubMed]
- Johnson, E.E.; Hamer, R.; Nora, R.M.; Tan, B.; Eisenstein, N.; Engelhart, C. The Lie/Bet Questionnaire for screening pathological gamblers. Psychol. Rep. 1997, 80, 83–88. [Google Scholar] [CrossRef] [PubMed]
- Maremmani, A.G.I.; Pacini, M.; Maremmani, I. What we have learned from the Methadone Maintenance Treatment of Dual Disorder Heroin Use Disorder patients. Int. J. Environ. Res. Public Health 2019, 16, 447. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- INPES. Baromètre Santé Médecins Généralistes; INPES: Paris, France, 2009. [Google Scholar]
- OFDT. Drogues, Chiffres Clés, 8th ed.; OFDT: Paris, France, 2019. [Google Scholar]
- Brisacier, A. Tableau de Bord «Traitements de Substituion aux Opiacés»; OFDT: Paris, France, 2018. [Google Scholar]
Variables | MTD (n = 178) | BHD (n = 79) | p |
---|---|---|---|
Socio-demographic characteristics | |||
Gender (%-n males) | 74.7% (133) | 74.7% (59) | 1 |
Current Age (y) | 33.8 | 37.2 | <0.001 |
Age at opioid initiation (y) | 20.3 | 20.9 | 0.33 |
Age at opioid dependence (y) | 22.3 | 23.9 | 0.14 |
Age at first attempt to quit (y) | 25.4 | 27.3 | 0.07 |
Previous strategies for attempting to quit (%-n) | 0.13 | ||
History of opioid withdrawal | 38.6% (68) | 61.3% (39) | |
History of previous OMT prescription | 49.3% (108) | 50.6% (40) | |
Living conditions (%-n) | |||
Marital status (% living as a couple) | 37.6% (67) | 42.3% (33) | 0.49 |
Stable housing | 88.1% (156) | 92.3% (72) | 0.38 |
Social support | 92.6% (164) | 92.3% (72) | 1 |
Education attainment > 12 y (%) | 13.2% (23) | 14.4% (11) | 0.69 |
Work status and financial situation % (n) | |||
Active workers | 42.7% (76) | 52.5% (41) | 0.3 |
Debt | 39.7% (70) | 31.1% (24) | 0.20 |
Opioid use disorder characteristics | |||
Opioid mainly used | 0.047 | ||
Heroin | 93.2% (165) | 84.8% (67) | |
Non-medical codeine or morphine | 3.9% (7) | 11.3% (9) | |
Non-medical buprenorphine | 2.8% (5) | 3.8% (3) | |
Main route of administration of heroin or non-medical opioid | 0.028 | ||
Nasal | 69.0% (107) | 68.0% (49) | |
Intravenous | 29.0 (45) | 22.2 (16) | |
Oral | 1.9% (3) | 9.7% (7) | |
Type of OUD damage | |||
Financial | 75.3% (134) | 63.3% (50) | 0.05 |
Social-affective(familial, relationnal) | 77.5% (138) | 54.4% (43) | <0.001 |
Psychiatric | 72.4% (129) | 62.0% (49) | 0.10 |
Professional | 61.8% (110) | 41.7% (33) | 0.004 |
Legal | 53.3% (95) | 40.5% (32) | 0.06 |
Somatic | 37.6% (67) | 21.5% (17) | 0.01 |
Associated problematic substance use | |||
Alcohol | 57.1% (80) | 46.7% (29) | 0.22 |
Amphetamine | 25.5% (22) | 21.7 % (5) | 0.79 |
Barbiturate | 29.8% (23) | 16.6 (5) | 0.22 |
Cannabis | 29.4% (38) | 18.8 (10) | 0.19 |
Cocaine | 36.9% (44) | 24.4 (10) | 0.18 |
LSD | 27.5% (22) | 15.0% (3) | 0.38 |
Variable | OR [2.5–97.5%] | p-Value |
---|---|---|
Somatic damage | 2.25 [0.96–5.60] | 0.069 |
Socio-affective damage | 2.63 [1.35–5.15] | 0.004 |
Professional damage | 1.80 [0.96–3.41] | 0.069 |
Age | 0.94 [0.90–0.98] | 0.004 |
Main route of administration of heroin or non-medical opioid: oral or sublingual | 0.22 [0.04–0.89] | 0.04 |
Main route of administration of heroin or non-medical opioid: IV | 0.98 [0.38–2.48] | 0.9 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Guillou-Landreat, M.; Dany, A.; Challet-Bouju, G.; Laforgue, E.; Leboucher, J.; Benoit Hardouin, J.; Victorri-Vigneau, C.; Grall-Bronnec, M. What Differs between Patients under Methadone and under Buprenorphine for Opioid Use Disorder (OUD) in Daily Clinical Practice in France? A Short Report. Int. J. Environ. Res. Public Health 2021, 18, 1425. https://doi.org/10.3390/ijerph18041425
Guillou-Landreat M, Dany A, Challet-Bouju G, Laforgue E, Leboucher J, Benoit Hardouin J, Victorri-Vigneau C, Grall-Bronnec M. What Differs between Patients under Methadone and under Buprenorphine for Opioid Use Disorder (OUD) in Daily Clinical Practice in France? A Short Report. International Journal of Environmental Research and Public Health. 2021; 18(4):1425. https://doi.org/10.3390/ijerph18041425
Chicago/Turabian StyleGuillou-Landreat, Morgane, Antoine Dany, Gaëlle Challet-Bouju, Edouard Laforgue, Juliette Leboucher, Jean Benoit Hardouin, Caroline Victorri-Vigneau, and Marie Grall-Bronnec. 2021. "What Differs between Patients under Methadone and under Buprenorphine for Opioid Use Disorder (OUD) in Daily Clinical Practice in France? A Short Report" International Journal of Environmental Research and Public Health 18, no. 4: 1425. https://doi.org/10.3390/ijerph18041425